➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
McKinsey
Boehringer Ingelheim
Colorcon

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INFLUENZA VACCINE LIVE INTRANASAL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for influenza vaccine live intranasal

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01591473 ↗ Safety Study of FluMist With and Without Ampligen Active, not recruiting Hemispherx Biopharma Phase 1/Phase 2 2012-04-01 The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.
NCT01866540 ↗ Immune Response To Intranasal Influenza Vaccination Enrolling by invitation Haukeland University Hospital N/A 2012-10-01 This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man.
NCT01866540 ↗ Immune Response To Intranasal Influenza Vaccination Enrolling by invitation University of Bergen N/A 2012-10-01 This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for influenza vaccine live intranasal

Condition Name

Condition Name for influenza vaccine live intranasal
Intervention Trials
Influenza 1
Egg Hypersensitivity 1
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for influenza vaccine live intranasal
Intervention Trials
Influenza, Human 4
Hypertrophy 1
Severe Acute Respiratory Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for influenza vaccine live intranasal

Trials by Country

Trials by Country for influenza vaccine live intranasal
Location Trials
United Kingdom 2
United States 1
Gambia 1
Norway 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for influenza vaccine live intranasal
Location Trials
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for influenza vaccine live intranasal

Clinical Trial Phase

Clinical Trial Phase for influenza vaccine live intranasal
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for influenza vaccine live intranasal
Clinical Trial Phase Trials
Not yet recruiting 4
Completed 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for influenza vaccine live intranasal

Sponsor Name

Sponsor Name for influenza vaccine live intranasal
Sponsor Trials
Public Health England 3
Imperial College London 2
Haukeland University Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for influenza vaccine live intranasal
Sponsor Trials
Other 22
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
AstraZeneca
Harvard Business School
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.